John M Ringman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
  2. pmc The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families
    Jill Murrell
    Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202 5126, USA
    Neurogenetics 7:277-9. 2006
  3. pmc Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Laboratory of Neuro Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
    Hum Brain Mapp 34:3308-19. 2013
  4. pmc Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations
    Grace J Lee
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    J Neurol Neurosurg Psychiatry 84:154-62. 2013
  5. pmc Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
    Arch Neurol 69:757-64. 2012
  6. pmc Increased fMRI signal with age in familial Alzheimer's disease mutation carriers
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurobiol Aging 33:424.e11-21. 2012
  7. pmc Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease
    Liana G Apostolova
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 32:118-25. 2011
  8. pmc Impaired default network functional connectivity in autosomal dominant Alzheimer disease
    Jasmeer P Chhatwal
    Department of Neurology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Neurology 81:736-44. 2013
  9. pmc Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, University of California at Los Angeles, Los Angeles, CA 90095 7334, USA
    Dement Geriatr Cogn Disord 33:219-25. 2012
  10. pmc Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cereb Cortex 21:877-83. 2011

Detail Information

Publications25

  1. ncbi request reprint The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
    ..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
  2. pmc The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families
    Jill Murrell
    Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202 5126, USA
    Neurogenetics 7:277-9. 2006
    ....
  3. pmc Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Laboratory of Neuro Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
    Hum Brain Mapp 34:3308-19. 2013
    ..Poorer performing carriers showed greater retrieval period signal, including in the frontal and temporal lobes, suggesting underlying pathological processes...
  4. pmc Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations
    Grace J Lee
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    J Neurol Neurosurg Psychiatry 84:154-62. 2013
    ..Using tensor-based morphometry (TBM), we examined brain volume differences between presymptomatic and symptomatic FAD mutation carriers and non-carrier (NC) relatives...
  5. pmc Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
    Arch Neurol 69:757-64. 2012
    ..To study the effect of familial Alzheimer disease (FAD) mutations and APOE genotype on plasma signaling protein levels...
  6. pmc Increased fMRI signal with age in familial Alzheimer's disease mutation carriers
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurobiol Aging 33:424.e11-21. 2012
    ..This suggests that during novelty encoding, increased fMRI activity in the temporal lobe may relate to incipient AD processes...
  7. pmc Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease
    Liana G Apostolova
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 32:118-25. 2011
    ..Both familial and sporadic Alzheimer's disease (AD) result in progressive cortical and subcortical atrophy. Familial autosomal dominant AD (FAD) allows us to study AD brain changes presymptomatically...
  8. pmc Impaired default network functional connectivity in autosomal dominant Alzheimer disease
    Jasmeer P Chhatwal
    Department of Neurology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Neurology 81:736-44. 2013
    ....
  9. pmc Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, University of California at Los Angeles, Los Angeles, CA 90095 7334, USA
    Dement Geriatr Cogn Disord 33:219-25. 2012
    ..We asked if consequently, oxidation of methionine residues to methionine sulfoxide (MetO) was increased in plasma proteins of persons carrying familial AD (FAD) mutations...
  10. pmc Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cereb Cortex 21:877-83. 2011
    ..Our findings of increased fMRI activation associated with APOE genotype but not with FAD mutations suggest that APOE exerts an effect on the BOLD signal that is not readily explained as a compensatory phenomenon...
  11. pmc Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults
    MEREDITH N BRASKIE
    Laboratory of Neuro Imaging, Department of Neurology, University of California, School of Medicine, Los Angeles, California 90095, USA
    J Neurosci 31:6764-70. 2011
    ..Young healthy carriers of the CLU gene risk variant showed a distinct profile of lower white matter integrity that may increase vulnerability to developing AD later in life...
  12. pmc Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease
    Anne M Fagan
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Sci Transl Med 6:226ra30. 2014
    ..If corroborated, this pattern may influence the definition of a positive neurodegenerative biomarker outcome in clinical trials. ..
  13. pmc Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases
    Giovanni Coppola
    Department of Neurology, University of California, Los Angeles, CA, USA
    Hum Mol Genet 21:3500-12. 2012
    ....
  14. pmc Complexity and synchronicity of resting state blood oxygenation level-dependent (BOLD) functional MRI in normal aging and cognitive decline
    Collin Y Liu
    Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA
    J Magn Reson Imaging 38:36-45. 2013
    ....
  15. pmc Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease
    Aditi Joshi
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA
    J Neurol 259:2182-8. 2012
    ..These may represent differences in pathophysiology between FAD and NF-EAD and in some contexts such findings should lead to genetic counseling and appropriate recommendations for genetic testing for FAD...
  16. ncbi request reprint An update on the diagnosis and management of dementing conditions
    Marwan Maalouf
    Department of Neurology, Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ, USA
    Rev Neurol Dis 8:e68-87. 2011
    ....
  17. pmc Clinical and biomarker changes in dominantly inherited Alzheimer's disease
    Randall J Bateman
    Washington University School of Medicine, Department of Neurology, 660 S Euclid Ave, Box 8111, St Louis, MO 63110, USA
    N Engl J Med 367:795-804. 2012
    ..Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease...
  18. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  19. pmc Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, California, USA
    Arch Neurol 66:448-57. 2009
    ..LR11 protein is reduced in patients with late-onset AD, and LR11 polymorphisms have been associated with late-onset AD...
  20. ncbi request reprint Current and emerging pharmacological treatment options for dementia
    John M Ringman
    Department of Neurology, Alzheimer s Disease Research Center, University of California, Los Angeles, CA 90095 1769, USA
    Behav Neurol 17:5-16. 2006
    ..Their clinical utility is controversial. Many novel approaches that promise to provide more effective treatments are currently being pursued...
  21. ncbi request reprint The Thr354Ile substitution in PSEN1:: disease-causing mutation or polymorphism?
    Peiyee Lee
    Department of Neurology, University of California Los Angeles, 90095 1769, USA
    Neurology 66:1955-6. 2006
  22. pmc Neuroimaging measures as endophenotypes in Alzheimer's disease
    MEREDITH N BRASKIE
    Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, 635 Charles Young Drive South, Suite 225, Los Angeles, CA 90095, USA
    Int J Alzheimers Dis 2011:490140. 2011
    ..Imaging measures might also clarify the specific mechanisms by which proposed risk factors influence the brain...
  23. doi request reprint Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature review
    John M Ringman
    Alzheimer s Disease Research Center, Department of Neurology, University of California, Los Angeles, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095 7226, USA
    Arch Neurol 65:412-5. 2008
    ..To describe a case of young-onset Alzheimer disease (AD) due to mosaicism for trisomy 21...
  24. doi request reprint Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers
    John M Ringman
    Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 25:380-4. 2008
    ..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)...
  25. ncbi request reprint Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations
    John M Ringman
    UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Brain 130:1767-76. 2007
    ..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...